Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04817826
Title TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (INFINITY)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gruppo Oncologico del Nord-Ovest
Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST